Overview
Neogen Q1 2026 revenue of $209.2 mln beats analyst expectations
Adjusted Net Income for Q1 beats estimates, driven by operational adjustments
Company completed divestiture and repaid $100 mln of debt
Outlook
Company reaffirms FY2026 revenue guidance of $820 mln to $840 mln
Neogen expects FY2026 adjusted EBITDA between $165 mln and $175 mln
Capital expenditures for FY2026 expected to total approximately $50 mln
Result Drivers
REVENUE DECLINE - Total revenue decreased 3.6% due to divestitures and discontinued product lines, with core revenue slightly up by 0.3%
GROSS MARGIN IMPACT - Gross margin declined due to integration costs and lower revenue, but excluding these costs, margin was higher
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Revenue | Beat | $209.18 mln | $204.20 mln (4 Analysts) |
Q1 EPS | $0.17 | ||
Q1 Adjusted Net Income | Beat | $9.40 mln | $6 mln (1 Analyst) |
Q1 Net Income | $36.33 mln | ||
Q1 Adjusted EBITDA | Miss | $35.50 mln | $36.30 mln (3 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Neogen Corp is $7.25, about 19.7% above its October 8 closing price of $5.82
The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 14 three months ago
Press Release: ID:nBw8SMqZla
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)